San Diego – May 18, 2015—SNP Bio, Inc., a company developing genetic tests for determining disease risk, announced that Michael Liss, M.D. presented clinical data on “The Prostate Genetic Score (PGS) Stratifies Baseline Risk of Prostate Cancer and Improves PSA Performance in the PLCO Trial” during a session presentation at the 2015 American Urology Association 2015 Annual Conference.
The research investigated the ability of the PGS-33™ genetic risk score, SNP Bio's germline biomarker test of prostate cancer risk, to categorize disease risk in men participating in the NCI-sponsored PLCO (Prostate, Lung, Colorectal, and Ovarian) cancer screening trial and to determine the effects of PGS-33 on PSA performance.
A PGS-33 score was calculated on 2,244 patients from the PCLO trial using an algorithm based on the patients’ genotypes using 33 SNPs or single nucleotide polymorphisms, associated with prostate cancer. The PGS-33 score, PSA test, family history of prostate cancer, abnormal digital rectal exam and history of smoking were associated with prostate cancer diagnosis. In multivariable analysis, the PGS-33 score was associated with prostate cancer diagnosis with an odds ratio of 1.68, or 95 percent confidence index.
The primary outcome of the study was the diagnosis of prostate cancer and the primary predictor was the PGS-33 score. The study concluded that germ-line DNA in the form of the PGS is able to stratify men regarding their risk of prostate cancer, which may have implications on who may benefit most from prostate cancer screening.
“We believe that PGS-33 has the potential of reversing the disturbing trend of an increasing proportion of men presenting with more aggressive disease,” said L. Blair Shamel, President and CEO of SNP Bio. “By preferentially screening those men at higher risk of prostate cancer, those in the highest PGS quartile, physicians can screen smarter and utilize PSA in men where it can be most effective, while minimizing the problem of over-screening.”
About PGS-33 SNP Bio’s initial test, PGS-33™ (Prostate Genetic Score), generates a Genetic Risk Score (GRS) for prostate cancer, to assist physicians in determining which men may benefit from early, risk-adapted screening. A positive family history of prostate cancer has long been an important risk factor justifying more active screening, but it is imperfect, subjective and often unclear or unknown. Because SNP Bio’s PGS-33 test provides an objective measure of a man’s genetic risk of developing prostate cancer, it can supplement family history in the decision to pursue screening. As such, it can be an essential tool in ensuring that men at high risk continue to be screened.
About SNP Bio
SNP Bio was founded to commercialize genetic tests that determine a patient's risk of developing serious diseases such as cancer. The company's initial test, the PGS-33™ prostate cancer Genetic Risk Score (GRS), is a genetic test designed to predict the lifetime risk of men to develop prostate cancer. The test supplements family history in the decision to offer active, biomarker-based screening. PGS-33 draws upon data from over 87,000 patients, and has been clinically validated in 20,000 patients from the most important prostate cancer detection studies. This Screen Smarter™ approach will allow determination of which men need risk-adapted screening, potentially leading to lower healthcare costs and reduced morbidity. SNP Bio, a privately held company, is based in San Diego, California. For more information, please visit www.snpbio.com.
Help employers find you! Check out all the jobs and post your resume.
The research investigated the ability of the PGS-33™ genetic risk score, SNP Bio's germline biomarker test of prostate cancer risk, to categorize disease risk in men participating in the NCI-sponsored PLCO (Prostate, Lung, Colorectal, and Ovarian) cancer screening trial and to determine the effects of PGS-33 on PSA performance.
A PGS-33 score was calculated on 2,244 patients from the PCLO trial using an algorithm based on the patients’ genotypes using 33 SNPs or single nucleotide polymorphisms, associated with prostate cancer. The PGS-33 score, PSA test, family history of prostate cancer, abnormal digital rectal exam and history of smoking were associated with prostate cancer diagnosis. In multivariable analysis, the PGS-33 score was associated with prostate cancer diagnosis with an odds ratio of 1.68, or 95 percent confidence index.
The primary outcome of the study was the diagnosis of prostate cancer and the primary predictor was the PGS-33 score. The study concluded that germ-line DNA in the form of the PGS is able to stratify men regarding their risk of prostate cancer, which may have implications on who may benefit most from prostate cancer screening.
“We believe that PGS-33 has the potential of reversing the disturbing trend of an increasing proportion of men presenting with more aggressive disease,” said L. Blair Shamel, President and CEO of SNP Bio. “By preferentially screening those men at higher risk of prostate cancer, those in the highest PGS quartile, physicians can screen smarter and utilize PSA in men where it can be most effective, while minimizing the problem of over-screening.”
About PGS-33 SNP Bio’s initial test, PGS-33™ (Prostate Genetic Score), generates a Genetic Risk Score (GRS) for prostate cancer, to assist physicians in determining which men may benefit from early, risk-adapted screening. A positive family history of prostate cancer has long been an important risk factor justifying more active screening, but it is imperfect, subjective and often unclear or unknown. Because SNP Bio’s PGS-33 test provides an objective measure of a man’s genetic risk of developing prostate cancer, it can supplement family history in the decision to pursue screening. As such, it can be an essential tool in ensuring that men at high risk continue to be screened.
About SNP Bio
SNP Bio was founded to commercialize genetic tests that determine a patient's risk of developing serious diseases such as cancer. The company's initial test, the PGS-33™ prostate cancer Genetic Risk Score (GRS), is a genetic test designed to predict the lifetime risk of men to develop prostate cancer. The test supplements family history in the decision to offer active, biomarker-based screening. PGS-33 draws upon data from over 87,000 patients, and has been clinically validated in 20,000 patients from the most important prostate cancer detection studies. This Screen Smarter™ approach will allow determination of which men need risk-adapted screening, potentially leading to lower healthcare costs and reduced morbidity. SNP Bio, a privately held company, is based in San Diego, California. For more information, please visit www.snpbio.com.
Help employers find you! Check out all the jobs and post your resume.
